Symbols / MTVA $1.52 -1.94%
MTVA Chart
About
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts. MetaVia Inc. operates as a subsidiary of Dong-A ST Co., Ltd.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 5.04M |
| Enterprise Value | -10.79M | Income | -16.22M | Sales | — |
| Book/sh | 2.88 | Cash/sh | 6.49 | Dividend Yield | — |
| Payout | 0.00% | Employees | 9 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | 0.53 | P/C | — |
| EV/EBITDA | 0.63 | EV/Sales | — | Quick Ratio | 1.69 |
| Current Ratio | 1.74 | Debt/Eq | 1.25 | LT Debt/Eq | — |
| EPS (ttm) | -10.45 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-06 08:00 | ROA | -58.41% |
| ROE | -168.18% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 3.32M |
| Shs Float | 981.54K | Short Float | 5.25% | Short Ratio | 0.31 |
| Short Interest | — | 52W High | 23.10 | 52W Low | 1.34 |
| Beta | 0.30 | Avg Volume | 232.98K | Volume | 55.92K |
| Target Price | $35.67 | Recom | Strong_buy | Prev Close | $1.55 |
| Price | $1.52 | Change | -1.94% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$35.67
Mean price target
2. Current target
$1.52
Latest analyst target
3. DCF / Fair value
$-60.03
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.52
Low
$7.00
High
$60.00
Mean
$35.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-06 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-05-19 | main | Maxim Group | Buy → Buy | $3 |
| 2025-04-16 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-03-21 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-12-30 | init | HC Wainwright & Co. | — → Buy | $12 |
- MetaVia Inc. Announces 1-for-11 Reverse Stock Split - PR Newswire ue, 02 Dec 2025 08
- Biotech MetaVia raises $9.3M to advance obesity drug trial DA-1726 - Stock Titan Fri, 16 Jan 2026 08
- MetaVia Inc. (MTVA) Stock Jumps After Reverse Split: What the New Price, Trial Data and 2026 Forecast Mean for Investors - TechStock² Sat, 06 Dec 2025 08
- IMG, MTVA, USREF, TGL: These Four Stocks Trade Ex-Reverse Split On Friday - Stocktwits hu, 04 Dec 2025 08
- We're Keeping An Eye On MetaVia's (NASDAQ:MTVA) Cash Burn Rate - simplywall.st Wed, 17 Sep 2025 07
- We're Keeping An Eye On MetaVia's (NASDAQ:MTVA) Cash Burn Rate - Yahoo Finance Wed, 17 Sep 2025 07
- MTVA Stock Soars as Analysts Weigh In - StocksToTrade Wed, 05 Nov 2025 08
- MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire hu, 06 Nov 2025 08
- U.S. farmers grow wary as Ag Economy Barometer falls to 100 in August 2024 - Stock Titan hu, 15 Jan 2026 08
- MetaVia Announces Reverse Stock Split to Meet Nasdaq Rules - TipRanks ue, 02 Dec 2025 08
- MetaVia announces 1-for-11 reverse stock split effective December 4 - Investing.com ue, 02 Dec 2025 08
- MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%… - Zacks Small Cap Research Wed, 16 Apr 2025 07
- MetaVia Completes Public Offering to Advance Obesity Drug - TipRanks Fri, 16 Jan 2026 08
- MetaVia’s obesity drug shows promising weight loss in early trials - Investing.com ue, 04 Nov 2025 08
- MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire hu, 07 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 28000 | — | — | Stock Award(Grant) at price 0.00 per share. | WOODWORTH MARSHALL H | Chief Financial Officer | — | 2026-01-23 00:00:00 | D |
| 1 | 32000 | — | — | Stock Award(Grant) at price 0.00 per share. | KIM HYUNG HEON | Chief Executive Officer | — | 2026-01-23 00:00:00 | D |
| 2 | 14200 | — | — | Stock Gift at price 0.00 per share. | WOODWORTH MARSHALL H | Chief Financial Officer | — | 2025-08-12 00:00:00 | D |
| 3 | 28147 | — | — | Stock Award(Grant) at price 0.00 per share. | STRICKLAND DAVID GORDON | Director | — | 2025-06-30 00:00:00 | D |
| 4 | 28147 | — | — | Stock Award(Grant) at price 0.00 per share. | KOVEN ANDREW IAN | Director | — | 2025-06-30 00:00:00 | D |
| 5 | 28147 | — | — | Stock Award(Grant) at price 0.00 per share. | GLICKMAN MARK A | Director | — | 2025-06-30 00:00:00 | D |
| 6 | 28147 | — | — | Stock Award(Grant) at price 0.00 per share. | GROVES JASON L | Director | — | 2025-06-30 00:00:00 | D |
| 7 | 28147 | — | — | Stock Award(Grant) at price 0.00 per share. | TURSI JAMES PATRICK | Director | — | 2025-06-30 00:00:00 | D |
| 8 | 28147 | — | — | Stock Award(Grant) at price 0.00 per share. | SALSBURY MICHAEL | Director | — | 2025-06-30 00:00:00 | D |
| 9 | 14200 | 9940 | — | Purchase at price 0.70 per share. | WOODWORTH MARSHALL H | Chief Financial Officer | — | 2025-06-04 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -29.09M | -18.84M | -11.48M | -15.24M |
| TotalUnusualItems | 297.00K | 2.96M | -275.00K | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 297.00K | 2.96M | -275.00K | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -27.59M | -12.47M | -13.97M | -15.28M |
| ReconciledDepreciation | 20.00K | 6.00K | 20.00K | 48.00K |
| EBITDA | -28.79M | -15.88M | -11.76M | -15.24M |
| EBIT | -28.81M | -15.89M | -11.78M | -15.28M |
| NetInterestIncome | 920.00K | 461.00K | -2.19M | 14.00K |
| InterestExpense | 0.00 | 2.19M | 0.00 | |
| InterestIncome | 920.00K | 461.00K | 0.00 | 14.00K |
| NormalizedIncome | -27.89M | -15.43M | -13.69M | -15.28M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -27.59M | -12.47M | -13.97M | -15.28M |
| TotalExpenses | 28.81M | 15.89M | 11.42M | 15.30M |
| TotalOperatingIncomeAsReported | -28.81M | -15.89M | -19.63M | -15.30M |
| DilutedAverageShares | 705.19K | 461.01K | 29.25K | 8.77K |
| BasicAverageShares | 705.19K | 461.01K | 29.25K | 8.77K |
| DilutedEPS | -39.16 | -27.06 | -477.84 | -1.74K |
| BasicEPS | -39.16 | -27.06 | -477.84 | -1.74K |
| DilutedNIAvailtoComStockholders | -27.59M | -12.47M | -13.97M | -15.28M |
| NetIncomeCommonStockholders | -27.59M | -12.47M | -13.97M | -15.28M |
| NetIncome | -27.59M | -12.47M | -13.97M | -15.28M |
| NetIncomeIncludingNoncontrollingInterests | -27.59M | -12.47M | -13.97M | -15.28M |
| NetIncomeContinuousOperations | -27.59M | -12.47M | -13.97M | -15.28M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -27.59M | -12.47M | -13.97M | -15.28M |
| OtherIncomeExpense | 297.00K | 2.96M | -358.00K | |
| OtherNonOperatingIncomeExpenses | -83.00K | |||
| SpecialIncomeCharges | 0.00 | -8.21M | 0.00 | |
| OtherSpecialCharges | 8.21M | |||
| GainOnSaleOfSecurity | 297.00K | 2.96M | 7.93M | |
| NetNonOperatingInterestIncomeExpense | 920.00K | 461.00K | -2.19M | 14.00K |
| TotalOtherFinanceCost | -920.00K | -461.00K | ||
| InterestExpenseNonOperating | 0.00 | 2.19M | 0.00 | |
| InterestIncomeNonOperating | 920.00K | 461.00K | 0.00 | 14.00K |
| OperatingIncome | -28.81M | -15.89M | -11.42M | -15.30M |
| OperatingExpense | 28.81M | 15.89M | 11.42M | 15.30M |
| ResearchAndDevelopment | 21.55M | 9.16M | 2.78M | 6.55M |
| SellingGeneralAndAdministration | 7.26M | 6.73M | 8.64M | 8.75M |
| GeneralAndAdministrativeExpense | 7.26M | 6.73M | 8.64M | 8.75M |
| OtherGandA | 7.26M | 6.73M | 8.64M | 8.75M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 785.19K | 446.00K | 289.05K | 10.10K |
| ShareIssued | 785.19K | 446.00K | 289.05K | 10.10K |
| TotalDebt | 136.00K | 203.00K | 0.00 | 71.00K |
| TangibleBookValue | 7.93M | 16.68M | 21.75M | 14.60M |
| InvestedCapital | 7.93M | 16.68M | 21.75M | 14.60M |
| WorkingCapital | 7.80M | 16.55M | 21.75M | 14.43M |
| NetTangibleAssets | 7.93M | 16.68M | 21.75M | 14.60M |
| CapitalLeaseObligations | 136.00K | 203.00K | 0.00 | 71.00K |
| CommonStockEquity | 7.93M | 16.68M | 21.75M | 14.60M |
| TotalCapitalization | 7.93M | 16.68M | 21.75M | 14.60M |
| TotalEquityGrossMinorityInterest | 7.93M | 16.68M | 21.75M | 14.60M |
| StockholdersEquity | 7.93M | 16.68M | 21.75M | 14.60M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 0.00 | 4.00K | |
| OtherEquityAdjustments | 4.00K | |||
| RetainedEarnings | -135.86M | -108.27M | -95.80M | -81.83M |
| AdditionalPaidInCapital | 143.78M | 124.94M | 117.52M | 96.42M |
| CapitalStock | 9.00K | 5.00K | 25.00K | 1.00K |
| CommonStock | 9.00K | 5.00K | 25.00K | 1.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 8.33M | 6.10M | 11.78M | 2.20M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 58.00K | 136.00K | 0.00 | 45.00K |
| LongTermDebtAndCapitalLeaseObligation | 58.00K | 136.00K | 0.00 | 45.00K |
| LongTermCapitalLeaseObligation | 58.00K | 136.00K | 0.00 | 45.00K |
| CurrentLiabilities | 8.27M | 5.96M | 11.78M | 2.16M |
| OtherCurrentLiabilities | 416.00K | 824.00K | 10.80M | 12.00K |
| CurrentDebtAndCapitalLeaseObligation | 78.00K | 67.00K | 26.00K | |
| CurrentCapitalLeaseObligation | 78.00K | 67.00K | 0.00 | 26.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 713.00K | 118.00K | ||
| PayablesAndAccruedExpenses | 7.06M | 4.95M | 988.00K | 2.13M |
| CurrentAccruedExpenses | 1.71M | 3.34M | 280.00K | 1.30M |
| Payables | 5.35M | 1.61M | 708.00K | 830.00K |
| DuetoRelatedPartiesCurrent | 1.47M | 789.00K | 0.00 | |
| AccountsPayable | 3.88M | 821.00K | 708.00K | 830.00K |
| TotalAssets | 16.26M | 22.78M | 33.53M | 16.80M |
| TotalNonCurrentAssets | 188.00K | 269.00K | 2.00K | 215.00K |
| OtherNonCurrentAssets | 21.00K | 21.00K | ||
| NetPPE | 167.00K | 248.00K | 2.00K | 215.00K |
| AccumulatedDepreciation | -54.00K | -34.00K | -28.00K | -111.00K |
| GrossPPE | 221.00K | 282.00K | 30.00K | 326.00K |
| OtherProperties | 133.00K | 202.00K | 263.00K | |
| MachineryFurnitureEquipment | 88.00K | 80.00K | 30.00K | 63.00K |
| CurrentAssets | 16.07M | 22.51M | 33.53M | 16.58M |
| OtherCurrentAssets | 77.00K | 168.00K | ||
| PrepaidAssets | 55.00K | 77.00K | 0.00 | 197.00K |
| CashCashEquivalentsAndShortTermInvestments | 16.02M | 22.43M | 33.36M | 16.39M |
| CashAndCashEquivalents | 16.02M | 22.43M | 33.36M | 16.39M |
| CashFinancial | 16.02M | 22.43M | 33.36M | 16.39M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -24.72M | -10.85M | -11.71M | -15.14M |
| IssuanceOfCapitalStock | 20.00M | 0.00 | 32.25M | 24.00M |
| CapitalExpenditure | -8.00K | -50.00K | -3.00K | |
| EndCashPosition | 16.02M | 22.43M | 33.36M | 16.39M |
| BeginningCashPosition | 22.43M | 33.36M | 16.39M | 10.09M |
| EffectOfExchangeRateChanges | 0.00 | -8.00K | ||
| ChangesInCash | -6.42M | -10.93M | 16.98M | 6.31M |
| FinancingCashFlow | 18.30M | -80.00K | 28.68M | 22.03M |
| CashFlowFromContinuingFinancingActivities | 18.30M | -80.00K | 28.68M | 22.03M |
| NetOtherFinancingCharges | -1.70M | -80.00K | -3.57M | -2.09M |
| ProceedsFromStockOptionExercised | 1.00K | 0.00 | 0.00 | 115.00K |
| NetPreferredStockIssuance | 0.00 | 32.25M | ||
| PreferredStockIssuance | 0.00 | 32.25M | ||
| NetCommonStockIssuance | 20.00M | 0.00 | 32.25M | 24.00M |
| CommonStockIssuance | 20.00M | 0.00 | 32.25M | 24.00M |
| InvestingCashFlow | -8.00K | -50.00K | 8.00K | -586.00K |
| CashFlowFromContinuingInvestingActivities | -8.00K | -50.00K | 8.00K | -586.00K |
| NetOtherInvestingChanges | -583.00K | |||
| NetPPEPurchaseAndSale | -8.00K | -50.00K | 8.00K | -3.00K |
| SaleOfPPE | 0.00 | 8.00K | 0.00 | |
| PurchaseOfPPE | -8.00K | -50.00K | 0.00 | -3.00K |
| OperatingCashFlow | -24.71M | -10.80M | -11.71M | -15.13M |
| CashFlowFromContinuingOperatingActivities | -24.71M | -10.80M | -11.71M | -15.13M |
| ChangeInWorkingCapital | 2.62M | 4.40M | -1.17M | -584.00K |
| ChangeInPayablesAndAccruedExpense | 2.60M | 4.33M | -1.23M | -980.00K |
| ChangeInAccruedExpense | -461.00K | 4.21M | -1.03M | 182.00K |
| ChangeInPayable | 3.06M | 113.00K | -202.00K | -1.16M |
| ChangeInAccountPayable | 3.06M | 113.00K | -202.00K | -1.16M |
| ChangeInPrepaidAssets | 20.00K | 70.00K | 64.00K | 396.00K |
| OtherNonCashItems | 4.00K | 1.00K | 8.22M | 24.00K |
| StockBasedCompensation | 538.00K | 222.00K | 854.00K | 662.00K |
| DepreciationAmortizationDepletion | 20.00K | 6.00K | 20.00K | 48.00K |
| DepreciationAndAmortization | 20.00K | 6.00K | 20.00K | 48.00K |
| Depreciation | 20.00K | 6.00K | 20.00K | 48.00K |
| OperatingGainsLosses | -297.00K | -2.96M | -5.67M | |
| GainLossOnInvestmentSecurities | -297.00K | -2.96M | -5.74M | |
| GainLossOnSaleOfPPE | 0.00 | 75.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -27.59M | -12.47M | -13.97M | -15.28M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MTVA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|